Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA extends expiration date for swath of Mylan’s Epipens amid shortage

August 21, 2018 By Sarah Faulkner

MylanIn an attempt to mitigate an ongoing shortage of Epipen auto-injectors, the FDA today extended the expiration date of specific lots of 0.3-mg devices by four months.

The move to extend the expiration dates beyond the approved 20-month shelf-life is based on stability data provided by Mylan (NSDQ:MYL) to the FDA, the U.S. regulatory agency reported.

“Many patients rely on self-injectable epinephrine products, such as Epipen, to reverse life-threatening reactions to bee stings or other allergens for either themselves or for their children. We are doing everything we can to help mitigate shortages of these products, especially ahead of the back-to-school season,” Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation & Research, said in prepared remarks.

“We’ve completed the necessary reviews of the data to extend the expiration date by four months for specific lots of Epipen that are expired or close to expiring. We’re hopeful this action will ensure patients have access to this important medication and provide additional peace-of-mind to parents as the agency works with the manufacturer to increase supply,” Woodcock added.

Mylan reportedly told the FDA months ago that delays experienced by its manufacturing partner, Pfizer’s Meridian Medical Technologies, were straining its Epipen supply.

Earlier this year, a survey from the advocacy group Food Allergy Research & Education found that hundreds of people across the U.S. have had trouble getting an Epipen.

Some patients reported waiting weeks to find the life-saving device, while others were unable to get an Epipen at all, according to a report from Bloomberg.

Several epinephrine auto-injector manufacturers have reported shortages, according to the U.S. regulatory agency’s website, including Impax Laboratories (NSDQ:IPXL), Mylan and Hospira.

The U.S. is not the only country facing an Epipen shortage; similar challenges have cropped up in Canada and the U.K. In Canada, the problem is especially dire, as there are no alternatives to Mylan’s Epipen on the market.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Wall Street Beat Tagged With: Mylan

IN CASE YOU MISSED IT

  • Eitan Group signs service agreement with Integrated Medical Systems
  • Beta Bionics’ bionic pancreas wins breakthrough status from FDA
  • FDA details framework for abbreviated 510(k) medical device review pathway
  • Aptar wins FDA clearance for ready-to-use seizure treatment device
  • Proteus Digital Health restructuring amid reported funding woes
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS